PD 184352

Cat. No. 4237

PD 184352 C17H14ClF2IN2O2 [212631-79-3]

Price and Availability

For PD 184352 pricing & availability please select your country from the drop down menu:
Submit
By clicking submit you agree to accept a cookie from Tocris Bioscience. For details, please read our privacy and cookie policy.

Alternative Name: CI-1040

Chemical Name: 2-[(2-Chloro-4-iodophenyl)amino]-N-cyclopropylmethoxy)-3,4-difluorobenzamide

Biological Activity

Selective MEK inhibitor (Ki = 300 nM in vitro). Suppresses FGF-mediated angiogenesis in vivo and decreases VEGF expression. Enhances the therapeutic efficacy of taxol (Cat. No. 1097) in vivo. Orally active.

Licensing Information

Sold for research purposes under agreement from Pfizer Inc.

Technical Data

M.Wt:
478.66
Formula:
C17H14ClF2IN2O2
Solubility:
Soluble to 100 mM in DMSO and to 25 mM in ethanol
Storage:
Store at +4°C
CAS No:
212631-79-3

The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.

Certificate of Analysis / Product Datasheet / Safety Datasheet

Solit et al (2006) BRAF mutation predicts sensitivity to MEK inhibition. Nature 439 358. PMID: 16273091.

McDaid et al (2005) Enhancement of the therapeutic efficacy of taxol by the mitogen-activated protein kinase kinase inhibitor CI-1040 in nude mice bearing human heterotransplants. Cancer Res. 65 2854. PMID: 15805287.

Allen et al (2003) CI-1040 (PD184252), a targeted signal transduction inhibitor of MEK (MAPKK). Semin.Oncol. 30 105. PMID: 14613031.

If you know of a relevant reference for this product please let us know.

Citations are publications that use Tocris products. Selected citations for PD 184352 include:

Wang et al (2015) Activation of protein synthesis in mouse uterine epithelial cells by estradiol-17β is mediated by a PKC-ERK1/2-mTOR signaling pathway. BMC Res Notes 112 E1382. PMID: 25733860.

Martin et al (2014) miR-155 induced transcriptome changes in the MCF-7 breast cancer cell line leads to enhanced mitogen activated protein kinase signaling. J Exp Bot 5 353. PMID: 25352952.

Wouters et al (2014) Central role for protein kinase C in oxytocin and epidermal growth factor stimulated cyclooxygenase 2 expression in human myometrial cells. Genes Cancer 7 357. PMID: 24916153.

Do you know of a great paper that uses PD 184352 from Tocris? If so please let us know.

View Related Products by Target

MEK

View Related Products by Product Action

Keywords: PD 184352, supplier, pfizer, mek1, mek2, mkk1, mkk2, inhibitors, inhibits, selective, mapk, signaling, signalling, map, kinases, PD184352, CI1040, Tocris Bioscience, MEK Inhibitor products

Quick Order

Find multiple products by catalog number

divider line

Cancer Research Product Guide

Cancer Research Product Guide

Our Cancer Research Guide highlights over 750 products for cancer research. Request copy or view PDF today.

divider line

Kinase Inhibitor Toolbox

80 Kinase inhibitors
pre-dissolved in DMSO

Kinase Inhibitor Toolbox

Includes many of the latest kinase inhibitors to become commercially available. Covers a wide range of kinase targets including EGFR, MAPK and CDK.

divider line

Kinases Product Listing

Kinases Product Listing

Our Kinase listing highlights over 400 products for kinase research. Request copy or view PDF today.

divider line

Pain Research Product Guide

Pain Research Product Guide

Our Pain guide highlights over 280 products for Pain research. Request copy or view PDF today.

divider line

MAPK Signaling Review

Written by Aroon S. Karra and Melanie H. Cobb

MAPK Signaling  Scientific Review

Our MAPK signaling review gives an overview of the MAPK signaling cascade and summarizes small molecule inhibitors of the pathway. Request copy or view PDF today.

divider line

MAPK Pathway

MAPK Signaling Pathway

The MAPK family kinases respond to extracellular stimuli such as heat and stress to mediate intracellular signals. View pathway or download PDF today.

divider line

New Products in this Area

TDZD 8

Selective non-ATP competitive inhibitor of GSK 3β

BI 605906

Selective IKKβ inhibitor

GSK 319347A

Potent and selective IKKε inhibitor

FRAX 597

Potent group I PAK inhibitor

MRT 68921 dihydrochloride

Potent ULK inhibitor; inhibits autophagy

AM 2394

Potent glucokinase activator; orally bioavailable

eCF 309

Potent mTOR inhibitor

PF 3758309 dihydrochloride

Potent PAK4 inhibitor; orally available

AZ Dyrk1B 33

Potent and selective Dyrk1B kinase inhibitor

PF 06409577

Potent and selective allosteric activator of AMPK

Perifosine

PKB/Akt inhibitor; also modulates Kv2.1 current

RAF 265

Raf kinase and VEGFR-2 inhibitor

CZC 25146

Potent LRRK2 inhibitor

Ro 3280

Potent and selective PLK1 inhibitor

RMM 46

MSK/RSK family kinase inhibitor

LTURM 34

Potent DNA-PK inhibitor

MLi-2

Potent and selective LRRK2 inhibitor

LTURM 36

PI 3-kinase δ inhibitor

PI 3065

Potent and selective PI 3-kinase p110δ inhibitor

AZ PFKFB3 67

Potent and selective PFKFB3 inhibitor

STOCK2S 26016

Lysine deficient protein kinase (WNK) signaling inhibitor

Sign-up for new product e-alerts
divider line

Twitter Updates

Follow @Tocris on Twitter

Follow us on Twitter!

Tocris is now actively tweeting. For regular updates on news, events and special offers, follow @Tocris on Twitter.